Elevated serum type IV collagen: A sensitive indicator of the presence of cirrhosis in haemochromatosis

Journal of Hepatology

Volumn 31, Issue 1, 1999, Pages 47-52

  George, D Keith ^a   Ramm, Grant A ^a   Walker, Neal I ^b   Powell, Lawrie W ^a   Crawford, Darrell H G ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Cirrhosis; Collagen type IV; Haemochromatosis; Laminin; Markers of hepatic fibrosis; Tissue inhibitor of metalloproteinase 1

Indexed keywords

COLLAGEN TYPE 4; GELATINASE A; LAMININ; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; HEMOCHROMATOSIS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0033054006     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80162-7     Document Type: Article

References (35)

1. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long term survival in patients with hereditary hemochromatosis. Gastroenterology. 110:1996;1107-1119.
2. George DK, Powell LW. The screening, diagnosis and optimal management of haemochromatosis. Aliment Pharmacol Ther. 11:1997;631-639.
3. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 13:1996;399-408.
4. Jazwinska EC, Cullen LM, Busfield F, Pyper WR, Webb SI, Powell LW, et al. Haemochromatosis and HLA-H. Nat Genet. 14:1996;249-251.
5. Jouanolle AM, Gandon G, Jezequel P, Blayau M, Campion ML, Yaouanq J, et al. Haemochromatosis and HLA-H. Nat Genet. 14:1996;251-252.
6. The UK Haemochromatosis Consortium. A simple genetic test identifies 90% of UK patients with haemochromatosis. Gut. 41:1997;841-844.
7. Carella M, D'Ambrosio L, Totaro A, Grifa A, Valentino MA, Piperno A, et al. Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. Am J Hum Genet. 60:1997;828-832.
8. Plebani M, Burlina A. Biochemical markers of hepatic fibrosis. Clin Biochem. 24:1991;219-239.
9. Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aube C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology. 113:1997;1609-1616.
10. Murawaki Y, Ikuta Y, Nishimura Y, Koda M, Kawasaki H. Serum markers for connective tissue turnover in patients with chronic hepatitis B and chronic hepatitis C: a comparative analysis. J Hepatol. 23:1995;145-152.
11. Ueno T, Tamaki S, Sugawara H, Inuzuka S, Torimura T, Sata M, et al. Significance of serum tissue inhibitor of metalloproteinases in various liver diseases. J Hepatol. 24:1996;177-184.
12. Shahin M, Schuppan D, Waldherr R, Ristelli J, Ristelli L, Savolainen ER, et al. Serum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease. Hepatology. 15:1992;637-644.
13. Kasahara A, Hayashi N, Mochizuki K, Oshita M, Katayama K, Kato M, et al. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. J Hepatol. 26:1997;574-583.
14. Li J, Rosman A, Leo M, Nagai Y, Lieber C. Tissue inhibitor of metalloproteinase is increased in the serum of precirrhotic and cirrhotic alcoholic patients and can serve as a marker of fibrosis. Hepatology. 19:1994;1418-1423.
15. Murawaki Y, Ikuta K, Koda M, Kawasaki H. Serum type III procollagen peptide, type IV collagen 7S domain, central triplehelix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology. Hepatology. 20:1994;780-787.
16. Murawaki Y, Ikuta Y, Koda M, Yamada S, Kawasaki H. Comparison of serum 7S fragment of type IV collagen and serum central triple-helix of type IV collagen for assessment of liver fibrosis in patients with chronic viral liver disease. J Hepatol. 24:1996;148-154.
17. Hirayama C, Suzuki H, Takada A, Fujisawa K, Tanikawa K, Igarashi S. Serum type IV collagen in various liver diseases in comparison with serum 7S collagen, laminin and type III procollagen peptide. J Gastroenterol. 31:1996;242-248.
18. Ueno T, Inuzuka S, Torimura T, Oohira H, Ko H, Obata K, et al. Significance of serum type IV collagen levels in various liver diseases. Measurement with a one-step sandwich enzyme immunoassay using monoclonal antibodies with specificity for pepsin-solublized type IV collagen. Scand J Gastroenterol. 27:1992;513-520.
19. Ueno T, Inuzuka S, Sata M, Koh H, Tamaki S, Kin M, et al. Serum hyaluronate predicts response to interferon-alpha therapy in patients with chronic hepatitis C. Hepatogastroenterology. 42:1995;522-527.
20. Hayasaka A, Schuppan D, Ohnishi K, Okuda K, Hahn EG. Serum concentrations of the carboxyterminal cross-linking domain of procollagen type IV (NC1) and the aminoterminal propeptide of procollagen type III (PIIIP) in chronic liver disease. J Hepatol. 10:1990;17-22.
21. Roberts FD, Sandford NL, Bradbaer RA, Cooksley WGE, Powell LW, Halliday JW. Serum procollagen-III-peptide: failure to reflect the extent of hepatic fibrosis. J Gastroenterol Hepatol. 1:1986;27-32.
22. Colombo M, Annoni G, Donato MF, Conte D, Martines D, Zaramella MG, et al. Serum type III procollagen peptide in alcoholic liver disease and idiopathic haemochromatosis: its relationship to hepatic fibrosis, activity of the disease and iron overload. Hepatology. 5:1985;475-479.
23. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 13:1991;372-374.
24. Kodoma S, Iwata K, Iwata H, Yamashita K, Hayakawa T. Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases. An application for rheumatoid arthritis serum and plasma. J Immunol Methods. 127:1990;103-108.
25. Iwata K. One-step sandwich enzyme immunoassay for human laminin using monoclonal antibodies. Clin Chim Acta. 191:1990;211-220.
26. Obata K, Iwata K, Ichida T, Inoue K, Matsumoto E, Muragaki Y, et al. One step sandwich enzyme immunoassay for human type IV collagen using monoclonal antibodies. Clin Chim Acta. 181:1989;293-304.
27. Fujimoto N, Mouri N, Iwaka K, Ohuchi E, Okada Y, Hayakawa T. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kD gelatinase/type IV collagenase) using monoclonal antibodies. Clin Chim Acta. 221:1993;91-103.
28. George DK, Ramm GA, Powell LW, Fletcher LM, Walker NI, Cowley LL, et al. Evidence for altered matrix degradation in genetic haemochromatosis. Gut. 42:1998;715-720.
29. Gressner AM, Kropf J. Concentration of laminin in serum related to the degree of oesophageal varices in fibrotic liver disease. Clin Chem. 34:1988;1006-1007.
30. Murawaki Y, Ikuta Y, Idobe Y, Kitamura Y, Kawasaki H. Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. J Hepatol. 26:1997;1213-1219.
31. Herbst H, Wege T, Milani S, Pelligrini G, Orzechowski HD, Bechstein WO, et al. Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am J Pathol. 150:1997;1647-1659.
32. Iredale JP, Murphy G, Hembry RM, Friedman SL, Arthur MJP. Human hepatic lipocytes synthesise tissue inhibitor of metalloproteinases-1: implications for regulation of matrix degradation in liver. J Clin Invest. 90:1992;282-287.
33. Jenson PD, Heickendorff L, Helwig-Larsen HM, Jenson FT, Christensen T, Ellegaard J. Serum procollagen III peptide concentration in iron overload. Eur J Haematol. 57:1996;157-164.
34. George DK, Ramm GA, Bridle KR, Fletcher LM, Powell LW, Crawford DHG. In vivo hepatic activities of matrix metalloproteinases-2, 3 and 9 are increased in prefibrotic animal and human iron overload. [abstract] Hepatology. 26:1997;A198.
35. Fellows IW, Stewart M, Jeffcoate WJ, Smith PG, Toghill PJ. Hepatocellular carcinoma in primary haemochromatosis in the absence of cirrhosis. Gut. 29:1988;1603-1606.